Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
SEATTLE, May 31, 2017 -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that management will present at the Jefferies 2017 Healthcare Conference in New York on Tuesday, June 6, 2017, at 8:00 a.m. Eastern time / 5:00 a.m. Pacific time.
A live audio webcast of the presentation will be available through the “Events & Presentations” page of the “News & Events” section of Cascadian Therapeutics’ website at www.cascadianrx.com. An archived edition of the session will be available later that day.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib (also known as ONT-380) is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.clinicaltrials.gov (Identifier: NCT02614794) or www.HER2CLIMB.com. For more information, please visit www.cascadianrx.com.
Investor and Media Contact: Monique Greer Cascadian Therapeutics 206-801-2107 [email protected]
